siRNA干扰技术在耐药性卵巢癌中的研究进展

doi:10.3969/j.issn.2095-378X.2018.02.013

摘要/Abstract

摘要： 卵巢癌死亡率居女性生殖系统恶性肿瘤之首,卵巢癌起病隐匿,早期无特殊临床表现,多数患者在晚期时才被发现,经肿瘤细胞减灭术及术后辅以铂类为基础的化疗后,部分患者出现病情缓解,但仍有一部分患者表现出化疗耐药以至于病情进展或复发。RNA干扰是由双链RNA介导的序列特异性的转录后基因沉默现象,小干扰RNA在RNA干扰过程中发挥核心作用。文章就小干扰RNA技术原理、递送及其近5年在耐药性卵巢癌方面的研究进展进行综述。

关键词: 小干扰RNA, 递送, 卵巢癌, 多药耐药性

Abstract: Ovarian cancer has the highest mortality rate among female reproductive cancer.Because it has no special clinical manifestation in early stage, and the majority of patients are diagnosed in advanced stage.This is a disease with a propensity to recur or deteriorate despite dramatic responses to the treatment of a combination of cytoreductive surgery and platinum-based chemotherapy.RNA interference is a sequence-specific posttranscriptional gene silencing triggered by double-stranded RNA, in which small interfering RNA plays a core role.This paper reviewed the research progress on small interfering RNA technical principle, delivery, and its application in drug-resistant ovarian cancer in recent five years.

Key words: siRNA, Delivery, Ovarian cancer, Multiple drug resistance

中图分类号:

R711.75

李霞, 童晓文. siRNA干扰技术在耐药性卵巢癌中的研究进展[J]. 外科研究与新技术, 2018, 7(2): 127-131.

LI Xia, TONG Xiaowen. Research progress on siRNA interference techniquein drug-resistant ovarian cancer[J]. Surgical Research and New Technique, 2018, 7(2): 127-131.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2] 徐梦娇,童晓文.游离DNA异常甲基化在卵巢癌中的研究进展[J].外科研究与新技术,2016,5(2):132-135.
[3] Bookman MA.Optimal primary therapy of ovarian cancer: Table 1[J].Ann Oncol,2016,27 (suppl 1):i58-i62.
[4] Wright AA, Bohlke K, Armstrong DK, et al.Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2016,34 (28):3460-3473.
[5] Marcus CS, Maxwell GL, Darcy KM, et al.Current approaches and challenges in managing and monitoring treatment response in ovarian cancer[J].J Cancer,2014,5(1):25-30.
[6] Fire A, Xu S, Montgomery MK, et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J].Nature,1998,391(6669):806-811.
[7] Smalheiser NR.The search for endogenous siRNAs in the mammalian brain[J].Exp Neurol,2012,235(2):455-463.
[8] Ipsaro JJ, Joshua-Tor L.From guide to target:molecular insights into eukaryotic RNA-interference machinery[J].Nat Struct Mol Biol,2015,22(1):20-28.
[9] Tsai HY, Chen CC, Conte D, et al.A ribonuclease coordinates siRNA amplification and mRNA cleavage during RNAi[J].Cell,2015,160(3):407-419.
[10] Wittrup A, Lieberman J.Knocking down disease: a progress report on siRNA therapeutics[J].Nat Rev Genet,2015,16(9):543-552.
[11] Wang J, Lu Z, Wientjes MG, et al.Delivery of siRNA therapeutics: barriers and carriers[J].The AAPS Journal,2010,12(4):492-503.
[12] Yan F, Shao LJ, Hu XY.Knockdown of UHRF1 by lentivirus-mediated shRNA inhibits ovarian cancer cell growth[J].Asian Pac J Cancer Prev,2015,16(4):1343-1348.
[13] Zhu YF, Gao GL, Tang SB, et al.Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro[J].Asian Pac J Trop Med,2013,6(4):265-272.
[14] Chen X, Zhang Y, Tang C, et al.Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis[J].Int J Pharm,2017,529(1-2):102-115.
[15] Liu L, Zheng M, Librizzi D, et al.Efficient and tumor targeted siRNA delivery by polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol)[J].Mol Pharm,2016,13(1):134-143.
[16] Shen J, Kim HC, Su H, et al.Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics[J].Theranostics,2014,4(5):487-497.
[17] Nascimento AV, Gattacceca F, Singh A, et al.Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models[J].Nanomedicine (Lond),2016,11(7):767-781.
[18] Teo PY, Yang C, Whilding LM, et al.Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine:strategies to enhance T cell killing[J].Adv Healthc Mater,2015,4(8):1180-1189.
[19] Guo S, Huang Y, Jiang Q, et al.Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte[J].ACS Nano,2010,4(9):5505-5511.
[20] Meng H, Mai WX, Zhang H, et al.Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo[J].ACS Nano,2013,7(2):994-1005.
[21] Chen Y, Xu M, Guo Y, et al.Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle[J].Nanotechnology,2017,28(2):25-101.
[22] Januchowski R, Sterzynska K, Zaorska K, et al.Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines[J].J Ovarian Res,2016,9(1):65.
[23] Kelly RJ, Thomas A, Rajan A, et al.A phase I/II study of sepantronium bromide (YM155,survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer[J].Ann Oncol,2013,24(10):2601-2606.
[24] Turner JG, Dawson JL, Grant S, et al.Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors[J].J Hematol Oncol,2016,9(1):73.
[25] Kovalev AA, Tsvetaeva DA, Grudinskaja TV.Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the develop-ment of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer[J].Exp Oncol,2013,35(4):287-290.
[26] Zhang Y, Sriraman SK, Kenny HA, et al.Reversal of chemoresistance in oivarian cancer by co-delivery of a p-glycoprotein inhibitor and paclitaxel in a liposomal platform[J].Mol Cancer Ther,2016,15(10):2282-2293.
[27] Zheng X, Andruska N, Lambrecht MJ, et al.Targeting multidrug-resistant ovarian cancer through estrogen receptor alpha dependent ATP depletion caused by hyperactivation of the unfolded protein response[J].Oncotarget,2018,9(19):14741-14753.
[28] Deng J, Guo Y, Jiang Z, et al.Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella[J].J Obstet Gynaecol Res,2015,41(4):615-622.
[29] Guo N, Gao C, Liu J, et al.Reversal of ovarian cancer multidrug resistance by a combination of LAH4-L1-siMDR1 nanocomplexes with chemotherapeutics[J].Mol Pharm,2018,15(5):1853-1861.
[30] Risnayanti C, Jang YS, Lee J, et al.PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer[J].Sci Rep,2018,8(1):7498.
[31] Li L, Mao X, Qin X, et al.Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2[J].Oncol Lett,2016,12(1):93-96.
[32] Liu X, Dong J, Cai W, et al.The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of Bcl-2 and Bax[J].Int J Gynecol Cancer,2017,27(8):1596-1601.
[33] He C, Lu K, Liu D, et al.Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells[J].J Am Chem Soc,2014,136(14):5181-5184.
[34] Kucukgoz Gulec U, Gumurdulu D, Guzel AB, et al.Prognostic importance of survivin,Ki-67,and topoisomerase II alpha in ovarian carcinoma[J].Arch Gynecol Obstet,2014,289(2):393-398.
[35] Yang X, Iyer AK, Singh A, et al.Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer[J].Pharm Res,2015,32(6):2097-2109.
[36] Salzano G, Navarro G, Trivedi MS, et al.Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J].Mol Cancer Ther,2015,14(4):1075-1084.